La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Beam Therapeutics Dividende
Dividende contrôle des critères 0/6
Beam Therapeutics does not have a record of paying a dividend.
Informations clés
n/a
Rendement du dividende
n/a
Ratio de distribution
| Rendement moyen de l'industrie | 2.0% |
| Prochaine date de paiement du dividende | n/a |
| Date ex-dividende | n/a |
| Dividende par action | n/a |
| Résultat par action | -US$1.81 |
| Prévisions de rendement du dividende à 3 ans | 0% |
Mises à jour récentes des dividendes
Pas de mise à jour
Recent updates
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12
Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Insufficient data to determine if BEAM's dividends per share have been stable in the past.
Dividende croissant: Insufficient data to determine if BEAM's dividend payments have been increasing.
Rendement des dividendes par rapport au marché
| Beam Therapeutics Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (BEAM) | n/a |
| 25% du marché (US) | 1.4% |
| 25% du marché (US) | 4.4% |
| Moyenne du secteur (Biotechs) | 2.0% |
| Prévisions des analystes dans 3 ans (BEAM) | 0% |
Dividende notable: Unable to evaluate BEAM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividende élevé: Unable to evaluate BEAM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Bénéfice distribué aux actionnaires
Couverture des revenus: Insufficient data to calculate BEAM's payout ratio to determine if its dividend payments are covered by earnings.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as BEAM has not reported any payouts.